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From research in human genetic diseases we are deriving cient research-laboratory technology to identify unique
the tools to predict disease before it has occurred, mak- mutations in the large, 27-exon RB1 gene (Blanquet et
ing it possible to use our resources to maintain health al. 1995). Lohmann et al. used a more efﬁcient strategy,
rather than to treat disease. Huge effort has been put screening every exon by a multiplex PCR-based assay
forth to map, clone, and analyze genes that cause human to detect any size change in the genomic fragments, fol-
disease, in order to achieve precisely this advantage. The lowed by heteroduplex analysis and sequencing. In addi-
research methods and approaches required are now rela- tion to strongly supporting the hypothesis that all retino-
tively standard. However, the process to incorporate this blastoma tumors have mutations in both alleles of RB1,
new knowledge of disease genes into clinical manage- this success rate indicates that RB1-mutation identiﬁca-
ment of families and into routine health care is not so tion is ready for implementation in health care.
clear. Previous studies, which counted affected offspring of
The rare tumor retinoblastoma has repeatedly been a unilateral patients, estimated risks, ranging from 15%
model that has revealed principles that subsequently (Bonaı¨ti-Pellie and Briard-Guillemot 1981) to 2%
were recognized to apply to much more common dis- (Draper et al. 1992), that unilateral patients would carry
eases: the mechanism of cancer induction common in a germ-line mutation in RB1. By their careful, precise
many human tumors, loss of heterozygosity (LOH), was molecular studies of RB1, identifying both RB1 muta-
discovered in retinoblastoma (Cavenee et al. 1983; God- tions present in the tumor and then checking the blood
bout et al. 1983); analysis of age at diagnosis of retino- of the patients speciﬁcally for those mutations, Loh-
blastoma tumors predicted the existence of tumor-sup- mann et al. show a convincing RB1 germ-line mutation
pressor genes (Knudson 1971); and the retinoblastoma in 17%.
gene (RB1) was the ﬁrst tumor-suppressor gene to be The types of mutations help to explain the reduced
cloned (Friend et al. 1986) and shown to be mutant in estimate derived from family studies, compared with
patients (Dunn et al. 1988). The biology of the protein molecular studies. Mosaicism for the molecular muta-
product of RB1 has ignited the ﬁeld of cell-cycle regula- tion was demonstrated in 2 patients and was suspected
tion, so that much more literature now refers to the in 1 other, of 39 patients studied. Mosaicism for an
retinoblastoma protein than to the disease. RB1 mutation would result in both reduced liklihood
In this issue of the Journal, Lohmann et al. (1997) of developing a retinoblastoma tumor and more unilat-
provide a thorough analysis of RB1 in a subset of pro- eral and unaffected carriers. Two patients with deletions
bands with retinoblastoma and show that the technol- encompassing undeﬁned genes adjacent to RB1 are in-
ogy for practical identiﬁcation of these mutations in cluded in this study of unilateral patients; such muta-
families is ready for implementation in health care. They tions are known to result in reduced numbers of tumors,
studied the tumors of unilaterally affected retinoblas- presumably because LOH does not lead to tumorigene-
toma patients who have no relatives with retinoblas- sis, since the cell cannot survive loss of the adjacent
toma. Of the mutations presumed to be present on both gene(s).
alleles, 81% were found. Previous studies used inefﬁ- In 29 (74%) of 39 patients, information was obtained
that was useful for the families and that signiﬁcantly
reduced the number of infant relatives that would re-
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tients conventionally have repeated clinical examination the investment that has been made in identifying human
disease genes such as RB1. A new kind of partnershipof the retina, some under general anaesthetic, during the
ﬁrst 4 years of life, in order to ﬁnd small retinoblastoma between research, innovative entrepreneurial activities,
and clinical management could accomplish this goal.tumors when early treatment can prevent blindness and
death. This results in a signiﬁcant expenditure, inconve- Since the scientist best understands the biology of the
particular gene and disease, continued involvement isnience, morbidity, and exposure to risk. On the other
hand, if the proband’s mutation is identiﬁed in a retino- critical to best ensure appropriate application to patient
care. The business world provides opportunities to keepblastoma family, only the few carrying the mutation
require the clinical surveillance. at the innovative-technology forefront and to achieve
economic beneﬁts of efﬁciency and scale. Clinical-serviceLohmann et al. speciﬁcally study and discuss RB1-
mutation identiﬁcation for isolated unilateral retinoblas- providers can deﬁne the necessary quality-control/pa-
tient-care interface—for example, genetic counseling—toma patients, using the tumor as a starting point. Since
such children might be the ﬁrst evidence of a low-pene- that is required to make the test appropriately available.
These needs have become obvious for RB1 testing.trance RB1 mutation in the family, it could be argued
that molecular studies are especially valuable for unilat- Retinoblastoma is a rare disease, and the best test
yet available is difﬁcult and much more expensive thaneral patients; otherwise, infant relatives might not be
screened at all, because of the conventional wisdom sug- established simple biochemical tests. The economic ben-
eﬁt of RB1-mutation identiﬁcation is seen only whengesting no risk, thereby allowing tumors to grow un-
heeded, as noted in the report of a large low-penetrance careful comparative economic studies recognize how ex-
pensive is the conventional care for these families. De-retinoblastoma family (Bremner et al. 1997).
Practical testing of unilateral patients requires that spite all the evidence, however, uninformed individuals
continue to expect the molecular results to be done freetumor be available in sufﬁcient quantity and quality to
allow identifcation of the RB1 mutations, which can of charge, as ‘‘research’’ or for less than cost, and they
fail to understand the signiﬁcant clinical advantage ofthen be speciﬁcally tested for in blood, as described by
Lohmann et al. Identiﬁcation of RB1 germ-line muta- the tests. For each diseased gene, prior to full implemen-
tation into clinical care the speciﬁc test must be shown totions in bilateral patients has an even greater advantage
in healthcare, since 100% are predicted to have a muta- be valid, sensitive, and clinically relevant and to reduce
health-care expenses; when these criteria are fulﬁlled,tion detectable in blood. The technology for RB1-muta-
tion detection described by Lohmann et al. is good but we need a process for implementation.
Once molecular testing is truly embraced in the clini-could be more efﬁcient; for example, if multiplex PCR
is performed quantitatively, the copy number of exons cal care of families, disease prediction will have very
signiﬁcant effects on the impact of that disease. Again,can be detected. As more RB1 individual mutations are
identiﬁed, the recurrent mutations due to genomic struc- retinoblastoma is an excellent example: not only does
the molecular strategy save health-care dollars, but in-ture become apparent and suggest a exon-testing order
that will make the overall strategy more efﬁcient. Such fants and children without the mutation can avoid inva-
sive procedures, and those who do have a germ-line RB1valuable information will be best utilized when all iden-
tiﬁed human RB1 mutations are available over the In- mutation can be promptly treated. The more common
diseases for which a similar case can be made are numer-ternet. Several Internet databases do contain RB1 muta-
tions from patients, but uniform terminology, entry of ous. At last our resources and efforts will deliver
‘‘health,’’ through prevention and early management ofmutations, and access to this information has not yet
been established. disease, which will replace the much more expensive
treatment of end-stage illness.At present, RB1-mutation identiﬁcation remains in
the research laboratory, as described by Lohmann et al.
This is suboptimal, for several reasons: research labora-
tories are not set up to provide adequate quality control References
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